Josh Grieger, PhD

"The rate of discovery for gene therapeutics in recent years is truly amazing. That takes on new meaning when we lower the cost of production and ensure ubiquitous access.”

Josh Grieger, PhD

Chief Technology Officer

Josh Grieger joined AskBio in 2017 and leads its manufacturing, process and analytical development initiatives. Previously, he was a co-founder and vice president of process development and manufacturing for Bamboo Therapeutics, Inc., where he led the GMP manufacturing and quality release of the rAAV drug product for the GAN Phase I clinical trial and supported the pre-IND for its Duchenne muscular dystrophy AAV gene therapy program. Pfizer acquired Bamboo Therapeutics in 2016, and Dr. Grieger served as the senior director of gene therapy and focused his efforts on process development and optimization of scalable rAAV vector manufacturing for early- and late-phase gene therapy clinical trials. From 2008 through 2015, he was employed by the UNC-Chapel Hill Gene Therapy Center as a post-doctoral research scientist, research associate professor and director of the UNC Vector Core facility. His research focused on the development of scalable transfection-based manufacturing process for rAAV vectors. The AskBio Pro10™ cell line was established through this work and led to the transition from adherent cell-based manufacturing of rAAV vectors to animal-derived component-free suspension cell manufacturing in WAVE and Stir tank bioreactors with associated scalable purification technology. Dr. Grieger also consulted for AskBio during that time and was critical in the Pro10 rAAV vector manufacturing process technology transfer to Baxter to support the hemophilia gene therapy pre-clinical and clinical programs.

Dr. Grieger received his doctorate degree from the University of North Carolina at Chapel Hill in the molecular biology and genetics program. He carried out his dissertation work in the R. Jude Samulski, PhD, laboratory.